- IBDEI3AU ; ; 04-FEB-2020
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
- Q:'DIFQR(358.4) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.4,119,0)
- ;;=CHEMO NURSE PROCEDURES^2^22
- ;;^UTILITY(U,$J,358.4,120,0)
- ;;=INFUSION DRUGS^7^22
- ;;^UTILITY(U,$J,358.4,121,0)
- ;;=BLOOD PRODUCTS^1^22
- ;;^UTILITY(U,$J,358.4,122,0)
- ;;=DIAGNOSTIC PROCEDURES^3^22
- ;;^UTILITY(U,$J,358.4,123,0)
- ;;=OTHER DRUGS^8^22
- ;;^UTILITY(U,$J,358.4,124,0)
- ;;=IMMUNIZATION ADMINISTRATION^5^22
- ;;^UTILITY(U,$J,358.4,125,0)
- ;;=IMMUNIZATIONS^6^22
- ;;^UTILITY(U,$J,358.4,126,0)
- ;;=PROLONGED SVC-MD/NP/PA^9^22
- ;;^UTILITY(U,$J,358.4,127,0)
- ;;=EDUCATION/TRAINING^4^22
- ;;^UTILITY(U,$J,358.4,128,0)
- ;;=NEW PATIENT^2^23
- ;;^UTILITY(U,$J,358.4,129,0)
- ;;=ESTABLISHED PATIENT^1^23
- ;;^UTILITY(U,$J,358.4,130,0)
- ;;=CONSULTATIONS^3^23
- ;;^UTILITY(U,$J,358.4,131,0)
- ;;=COMPLEX CHRONIC CARE^4^23
- ;;^UTILITY(U,$J,358.4,132,0)
- ;;=ANEMIA^1^24
- ;;^UTILITY(U,$J,358.4,133,0)
- ;;=ARTIFICIAL OPENING STATUS^2^24
- ;;^UTILITY(U,$J,358.4,134,0)
- ;;=BREASTS and GYN NEOPLASMS^3^24
- ;;^UTILITY(U,$J,358.4,135,0)
- ;;=COAGULATION DISORDERS^4^24
- ;;^UTILITY(U,$J,358.4,136,0)
- ;;=COUNSELING AND SCREENING^5^24
- ;;^UTILITY(U,$J,358.4,137,0)
- ;;=GENITOURINARY NEOPLASMS^6^24
- ;;^UTILITY(U,$J,358.4,138,0)
- ;;=GI CANCER^7^24
- ;;^UTILITY(U,$J,358.4,139,0)
- ;;=HEAD NECK AND LUNGS NEOPLASMS^8^24
- ;;^UTILITY(U,$J,358.4,140,0)
- ;;=HEMOGLOBINOPATHIES^9^24
- ;;^UTILITY(U,$J,358.4,141,0)
- ;;=LYMPHOID NEOPLASMS^10^24
- ;;^UTILITY(U,$J,358.4,142,0)
- ;;=METASTATIC SITES^13^24
- ;;^UTILITY(U,$J,358.4,143,0)
- ;;=MALIGNANT NEOPLASMS OF OTHER SITES^11^24
- ;;^UTILITY(U,$J,358.4,144,0)
- ;;=MYELOID NEOPLASMS AND DISORDERS^14^24
- ;;^UTILITY(U,$J,358.4,145,0)
- ;;=NEOPLASM OF UNCERTAIN BEHAVIOR^15^24
- ;;^UTILITY(U,$J,358.4,146,0)
- ;;=NEOPLASM OF UNSPECIFIED NATURE^16^24
- ;;^UTILITY(U,$J,358.4,147,0)
- ;;=PERSONAL HISTORY^19^24
- ;;^UTILITY(U,$J,358.4,148,0)
- ;;=MALNUTRITION^12^24
- ;;^UTILITY(U,$J,358.4,149,0)
- ;;=OTHER^18^24
- ;;^UTILITY(U,$J,358.4,150,0)
- ;;=SUICIDE IDEATIONS/ATTEMPTS^20^24
- ;;^UTILITY(U,$J,358.4,151,0)
- ;;=CHEST WALL AND NECK^1^25
- ;;^UTILITY(U,$J,358.4,152,0)
- ;;=THORACIC^2^25
- ;;^UTILITY(U,$J,358.4,153,0)
- ;;=OTHER PROCEDURES^3^25
- ;;^UTILITY(U,$J,358.4,154,0)
- ;;=NEW PATIENT^2^26
- ;;^UTILITY(U,$J,358.4,155,0)
- ;;=ESTABLISHED PATIENT^1^26
- ;;^UTILITY(U,$J,358.4,156,0)
- ;;=CONSULTATIONS^3^26
- ;;^UTILITY(U,$J,358.4,157,0)
- ;;=POST-OP FOLLOW-UP^4^26
- ;;^UTILITY(U,$J,358.4,158,0)
- ;;=GENERAL SIGNS & SYMPTOMS^3^27
- ;;^UTILITY(U,$J,358.4,159,0)
- ;;=AFTERCARE POST-OP^1^27
- ;;^UTILITY(U,$J,358.4,160,0)
- ;;=POST-OP COMPLICATIONS^5^27
- ;;^UTILITY(U,$J,358.4,161,0)
- ;;=CARDIOVASCULAR^2^27
- ;;^UTILITY(U,$J,358.4,162,0)
- ;;=RESPIRATORY^7^27
- ;;^UTILITY(U,$J,358.4,163,0)
- ;;=NEOPLASM^4^27
- ;;^UTILITY(U,$J,358.4,164,0)
- ;;=PRE-OP^6^27
- ;;^UTILITY(U,$J,358.4,165,0)
- ;;=SUICIDE IDEATION/ATTEMPTS^8^27
- ;;^UTILITY(U,$J,358.4,166,0)
- ;;=ESTABLISHED PATIENT^1^28
- ;;^UTILITY(U,$J,358.4,167,0)
- ;;=CONSULTATIONS/OPINIONS^2^28
- ;;^UTILITY(U,$J,358.4,168,0)
- ;;=NEW PATIENTS^3^28
- ;;^UTILITY(U,$J,358.4,169,0)
- ;;=NEUROLOGY/SEIZURE^7^29
- ;;^UTILITY(U,$J,358.4,170,0)
- ;;=EEG^4^29
- ;;^UTILITY(U,$J,358.4,171,0)
- ;;=SLEEP TESTING^9^29
- ;;^UTILITY(U,$J,358.4,172,0)
- ;;=MUSCLE TESTING/EMG^6^29
- ;;^UTILITY(U,$J,358.4,173,0)
- ;;=EVOKED POTENTIAL^5^29
- ;;^UTILITY(U,$J,358.4,174,0)
- ;;=BIOPSY^2^29
- ;;^UTILITY(U,$J,358.4,175,0)
- ;;=AUTONOMIC FUNCTION TESTS^1^29
- ;;^UTILITY(U,$J,358.4,176,0)
- ;;=STEREOTACTIC^10^29
- ;;^UTILITY(U,$J,358.4,177,0)
- ;;=EDUCATION^3^29
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3AU 3768 printed Mar 13, 2025@21:50:02 Page 2
- IBDEI3AU ; ; 04-FEB-2020
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
- +2 if 'DIFQR(358.4)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.4,119,0)
- +2 ;;=CHEMO NURSE PROCEDURES^2^22
- +3 ;;^UTILITY(U,$J,358.4,120,0)
- +4 ;;=INFUSION DRUGS^7^22
- +5 ;;^UTILITY(U,$J,358.4,121,0)
- +6 ;;=BLOOD PRODUCTS^1^22
- +7 ;;^UTILITY(U,$J,358.4,122,0)
- +8 ;;=DIAGNOSTIC PROCEDURES^3^22
- +9 ;;^UTILITY(U,$J,358.4,123,0)
- +10 ;;=OTHER DRUGS^8^22
- +11 ;;^UTILITY(U,$J,358.4,124,0)
- +12 ;;=IMMUNIZATION ADMINISTRATION^5^22
- +13 ;;^UTILITY(U,$J,358.4,125,0)
- +14 ;;=IMMUNIZATIONS^6^22
- +15 ;;^UTILITY(U,$J,358.4,126,0)
- +16 ;;=PROLONGED SVC-MD/NP/PA^9^22
- +17 ;;^UTILITY(U,$J,358.4,127,0)
- +18 ;;=EDUCATION/TRAINING^4^22
- +19 ;;^UTILITY(U,$J,358.4,128,0)
- +20 ;;=NEW PATIENT^2^23
- +21 ;;^UTILITY(U,$J,358.4,129,0)
- +22 ;;=ESTABLISHED PATIENT^1^23
- +23 ;;^UTILITY(U,$J,358.4,130,0)
- +24 ;;=CONSULTATIONS^3^23
- +25 ;;^UTILITY(U,$J,358.4,131,0)
- +26 ;;=COMPLEX CHRONIC CARE^4^23
- +27 ;;^UTILITY(U,$J,358.4,132,0)
- +28 ;;=ANEMIA^1^24
- +29 ;;^UTILITY(U,$J,358.4,133,0)
- +30 ;;=ARTIFICIAL OPENING STATUS^2^24
- +31 ;;^UTILITY(U,$J,358.4,134,0)
- +32 ;;=BREASTS and GYN NEOPLASMS^3^24
- +33 ;;^UTILITY(U,$J,358.4,135,0)
- +34 ;;=COAGULATION DISORDERS^4^24
- +35 ;;^UTILITY(U,$J,358.4,136,0)
- +36 ;;=COUNSELING AND SCREENING^5^24
- +37 ;;^UTILITY(U,$J,358.4,137,0)
- +38 ;;=GENITOURINARY NEOPLASMS^6^24
- +39 ;;^UTILITY(U,$J,358.4,138,0)
- +40 ;;=GI CANCER^7^24
- +41 ;;^UTILITY(U,$J,358.4,139,0)
- +42 ;;=HEAD NECK AND LUNGS NEOPLASMS^8^24
- +43 ;;^UTILITY(U,$J,358.4,140,0)
- +44 ;;=HEMOGLOBINOPATHIES^9^24
- +45 ;;^UTILITY(U,$J,358.4,141,0)
- +46 ;;=LYMPHOID NEOPLASMS^10^24
- +47 ;;^UTILITY(U,$J,358.4,142,0)
- +48 ;;=METASTATIC SITES^13^24
- +49 ;;^UTILITY(U,$J,358.4,143,0)
- +50 ;;=MALIGNANT NEOPLASMS OF OTHER SITES^11^24
- +51 ;;^UTILITY(U,$J,358.4,144,0)
- +52 ;;=MYELOID NEOPLASMS AND DISORDERS^14^24
- +53 ;;^UTILITY(U,$J,358.4,145,0)
- +54 ;;=NEOPLASM OF UNCERTAIN BEHAVIOR^15^24
- +55 ;;^UTILITY(U,$J,358.4,146,0)
- +56 ;;=NEOPLASM OF UNSPECIFIED NATURE^16^24
- +57 ;;^UTILITY(U,$J,358.4,147,0)
- +58 ;;=PERSONAL HISTORY^19^24
- +59 ;;^UTILITY(U,$J,358.4,148,0)
- +60 ;;=MALNUTRITION^12^24
- +61 ;;^UTILITY(U,$J,358.4,149,0)
- +62 ;;=OTHER^18^24
- +63 ;;^UTILITY(U,$J,358.4,150,0)
- +64 ;;=SUICIDE IDEATIONS/ATTEMPTS^20^24
- +65 ;;^UTILITY(U,$J,358.4,151,0)
- +66 ;;=CHEST WALL AND NECK^1^25
- +67 ;;^UTILITY(U,$J,358.4,152,0)
- +68 ;;=THORACIC^2^25
- +69 ;;^UTILITY(U,$J,358.4,153,0)
- +70 ;;=OTHER PROCEDURES^3^25
- +71 ;;^UTILITY(U,$J,358.4,154,0)
- +72 ;;=NEW PATIENT^2^26
- +73 ;;^UTILITY(U,$J,358.4,155,0)
- +74 ;;=ESTABLISHED PATIENT^1^26
- +75 ;;^UTILITY(U,$J,358.4,156,0)
- +76 ;;=CONSULTATIONS^3^26
- +77 ;;^UTILITY(U,$J,358.4,157,0)
- +78 ;;=POST-OP FOLLOW-UP^4^26
- +79 ;;^UTILITY(U,$J,358.4,158,0)
- +80 ;;=GENERAL SIGNS & SYMPTOMS^3^27
- +81 ;;^UTILITY(U,$J,358.4,159,0)
- +82 ;;=AFTERCARE POST-OP^1^27
- +83 ;;^UTILITY(U,$J,358.4,160,0)
- +84 ;;=POST-OP COMPLICATIONS^5^27
- +85 ;;^UTILITY(U,$J,358.4,161,0)
- +86 ;;=CARDIOVASCULAR^2^27
- +87 ;;^UTILITY(U,$J,358.4,162,0)
- +88 ;;=RESPIRATORY^7^27
- +89 ;;^UTILITY(U,$J,358.4,163,0)
- +90 ;;=NEOPLASM^4^27
- +91 ;;^UTILITY(U,$J,358.4,164,0)
- +92 ;;=PRE-OP^6^27
- +93 ;;^UTILITY(U,$J,358.4,165,0)
- +94 ;;=SUICIDE IDEATION/ATTEMPTS^8^27
- +95 ;;^UTILITY(U,$J,358.4,166,0)
- +96 ;;=ESTABLISHED PATIENT^1^28
- +97 ;;^UTILITY(U,$J,358.4,167,0)
- +98 ;;=CONSULTATIONS/OPINIONS^2^28
- +99 ;;^UTILITY(U,$J,358.4,168,0)
- +100 ;;=NEW PATIENTS^3^28
- +101 ;;^UTILITY(U,$J,358.4,169,0)
- +102 ;;=NEUROLOGY/SEIZURE^7^29
- +103 ;;^UTILITY(U,$J,358.4,170,0)
- +104 ;;=EEG^4^29
- +105 ;;^UTILITY(U,$J,358.4,171,0)
- +106 ;;=SLEEP TESTING^9^29
- +107 ;;^UTILITY(U,$J,358.4,172,0)
- +108 ;;=MUSCLE TESTING/EMG^6^29
- +109 ;;^UTILITY(U,$J,358.4,173,0)
- +110 ;;=EVOKED POTENTIAL^5^29
- +111 ;;^UTILITY(U,$J,358.4,174,0)
- +112 ;;=BIOPSY^2^29
- +113 ;;^UTILITY(U,$J,358.4,175,0)
- +114 ;;=AUTONOMIC FUNCTION TESTS^1^29
- +115 ;;^UTILITY(U,$J,358.4,176,0)
- +116 ;;=STEREOTACTIC^10^29
- +117 ;;^UTILITY(U,$J,358.4,177,0)
- +118 ;;=EDUCATION^3^29
